Genentech

Summary

Genentech appeared to be the Corporate Investor, which was created in 1976. The leading representative office of defined Corporate Investor is situated in the South San Francisco. The company was established in North America in United States.

The fund was created by Kenneth Lee, Robert Swanson. The overall number of key employees were 6.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Genentech, startups are often financed by HealthCare Ventures, Venrock, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are HealthCare Ventures, Yasuda Enterprise Development, Vertex Management. In the next rounds fund is usually obtained by Venrock, Topspin Partners, Third Rock Ventures.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight 23andMe, GlobeImmune, Kereos. We can highlight the next thriving fund investment areas, such as Therapeutics, Health Care. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.

Opposing the other organizations, this Genentech works on 15 percentage points more the average amount of lead investments. The top activity for fund was in 2005. The increased amount of exits for fund were in 2018. Speaking about the real fund results, this Corporate Investor is 2 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Genentech is 50-100 millions dollars. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars.